Biased Ligands. Better Drugs.

Press Releases

10/8/14 - Trevena Announces Early Completion of Enrollment of Phase 2a/b Study of TRV130 in Postoperative Pain

Trevena, Inc. (NASDAQ: TRVN), today announced that it has closed enrollment of its Phase 2a/b study of intravenous TRV130 in postoperative bunionectomy pain after enrolling a pilot phase and eight of ten planned study cohorts in a second phase. Read More

9/22/14 - Trevena Enters into $35 Million Tranched Term Loan Credit Facility
Trevena, Inc. (NASDAQ: TRVN), today announced that it has entered into a senior secured term loan credit facility providing for up to $35.0 million of funding, of which $2.0 million was drawn at closing. Read More

9/18/14 - Trevena Appoints Adam M. Koppel to the Board of Directors
Trevena, Inc. (NASDAQ: TRVN), today announced that Adam M. Koppel, M.D., Ph.D. has joined Trevena’s Board of Directors. Dr. Koppel replaces Christopher Mirabelli, Ph.D., managing director at HealthCare Ventures, who is stepping down from the Board following the Company’s recent initial public offering. Read More

9/16/14 - Trevena Granted Key U.S. Composition of Matter Patent for TRV130
Trevena, Inc. (NASDAQ: TRVN), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 8,835,488, “Opioid receptor ligands and methods of using and making same.” The patent covers TRV130, compositions comprising TRV130, and methods of using TRV130 and is expected to provide patent coverage for TRV130 until at least 2032. Trevena currently is testing TRV130 for the treatment of postoperative pain in a Phase 2a/b clinical trial. Read More

8/12/14 - Trevena Reports Second Quarter 2014 Financial Results
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced financial results for the quarter ended June 30, 2014. Read More

8/7/14 - Trevena CEO to Present at the Canaccord Genuity 34th Annual Growth Conference
Trevena, Inc. (NASDAQ: TRVN), today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 1:30 p.m. EDT at The InterContinental in Boston. Read More

8/6/14 - Trevena Initiates Phase 1 Multiple Ascending Dose Study of TRV734 for Acute and Chronic Pain
Trevena, Inc. (NASDAQ: TRVN), today announced the initiation of the next Phase 1 trial for TRV734, a novel drug candidate in development as an orally administered treatment for moderate-to-severe acute and chronic pain. Read More

8/5/14 - Trevena to Host Conference Call to Discuss Second Quarter 2014 Results on August 12
Trevena, Inc., today announced that it will host a conference call on Tuesday, August 12, 2014 at 8:30 a.m. EDT to discuss its financial and operational results for the second quarter ended June 30, 2014. Read More

8/5/14 - Trevena Granted Key U.S. Method of Use Patent for TRV027
Trevena, Inc. (NASDAQ: TRVN), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 8,796,204, "Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof," which covers methods of use for TRV027, including a method of treating acute heart failure. Read More

7/1/14 - Trevena Appoints Julie H. McHugh and Barbara Yanni to the Board of Directors
Trevena, Inc. (NASDAQ: TRVN), today announced that Julie H. McHugh, former president of Centocor and chief operating officer at Endo Health Solutions, and Barbara Yanni, former chief licensing officer at Merck & Co., have joined Trevena’s Board of Directors. Read More

6/24/14 - Results of Phase 1b Clinical Trial Comparing Trevena’s TRV130 to Morphine Published in the Journal Pain
Trevena, Inc. (NASDAQ: TRVN), today announced the publication of its Phase 1b data for TRV130 in the journal Pain. Read More

6/23/14 - Trevena Announces Positive Phase 1 Results for TRV734 for Acute and Chronic Pain
Trevena, Inc. (NASDAQ: TRVN) today announced positive results from its Phase 1 trial of TRV734, which Trevena is developing with the goal of providing improved analgesia while avoiding gastrointestinal and respiratory side effects typically associated with opioids. The study tested single ascending doses and the relative bioavailability of oral TRV734 in healthy subjects, and demonstrated that TRV734 is pharmacologically active at a range of safe and well-tolerated doses. Read More

5/27/14 - Trevena CEO to Present at the Jefferies 2014 Global Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 11:00 a.m. EDT in New York City. Read More

5/19/14 - Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting
Trevena, Inc. (NASDAQ: TRVN), today announced that it presented the trial design rationale for its ongoing Phase 2b BLAST-AHF Study of TRV027 in acute heart failure (AHF) at the European Society of Cardiology Heart Failure (ESC-HF) 2014 Meeting, which is taking place May 17 – 20, 2014 in Athens, Greece. Read More

5/15/14 - Trevena Appoints John M. Limongelli as General Counsel
Trevena, Inc. (NASDAQ: TRVN), today announced the appointment of John M. Limongelli, Esq., to the newly created position of Senior Vice President, General Counsel & Corporate Secretary, effective immediately. Read More

5/9/14 - Trevena Reports First Quarter 2014 Financial Results
Trevena, Inc. (NASDAQ: TRVN), today announced financial results for the quarter ended March 31, 2014. Read More

5/2/14 - Trevena to Host Conference Call on May 9th to Discuss First Quarter 2014 Financial Results and Recent Highlights
Trevena, Inc. (NASDAQ: TRVN), today announced that it will host a conference call on Friday, May 9, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2014. Read More

5/2/14 - Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130 at American Society of Pain Annual Meeting
Trevena, Inc. (NASDAQ: TRVN), announced that data from the Company’s Phase 1b trial of TRV130, a small molecule G protein biased ligand at the mu-opioid receptor, are being presented today in a poster session at the American Pain Society Annual Meeting in Tampa, Florida. Read More

5/1/14 - Trevena Initiates Phase 2 Study of TRV130 in Acute Postoperative Pain
Trevena, Inc. (NASDAQ: TRVN), today announced the initiation of a Phase 2a/b clinical trial with TRV130, a small molecule G protein biased ligand at the mu opioid receptor, which Trevena is developing as a first-line intravenous treatment for patients experiencing moderate to severe acute pain where intravenous administration is preferred. Read More

News Archive

Copyright © Trevena, Inc.